ABSTRACT
Background: We studied whether the variation of T-lymphocyte CD4+ (CD4) absolute count and percentage prior and after delivery could affect the decision process regarding HAART initiation in African HIV-infected pregnant women.
Methods:
Prospective cohort in Abidjan, Côte d'Ivoire before HAART was available.
Participating women received a perinatal antiretroviral prophylaxis (zidovudine + single-dose of nevirapine). CD4 count and percentage were measured by flow cytometry at baseline (32 weeks of amenorrhea) and at month-1after delivery. Signedrank test was used to compare the distributions of the CD4 absolute count and percentage values.
Results: 325 HIV-1-infected pregnant women were included. At baseline, the median CD4 count was 355 cells/mm 3 women who do not meet these criteria should receive short-course antiretroviral prophylaxis for PMTCT (4) . Although its efficacy for PMTCT is very high, the use of HAART during pregnancy in high-income countries has been associated with increased rates of preterm delivery (5, 6).
Furthermore, nevirapine (NVP)-containing HAART regimens are no longer recommended for women with CD4>250/mm 3 considering elevated risk of hepatotoxicity (7) . Thus, important treatment decisions may be taken during pregnancy, with potential consequences for the mother and her future child. CD4 and CD8 absolute count have been reported to be slightly modified during pregnancy with and without HIV infection with no clinical consequences described in high-income countries (8) . In sub-Saharan Africa, few studies have described the CD4 count variation in pregnancy but none has looked concomitantly at its implications for the therapeutic decisions to initiate HAART (9-11). The present study was performed in Abidjan, Côte d'Ivoire within a cohort of HIV-infected pregnant women who benefited from PMTCT short-course antiretroviral prophylaxis and were followed up to two year post-partum before access to HAART became possible. We investigated whether changes in CD4 count and percentage between the pre-and early post-partum periods could have consequences on the decision process regarding HAART initiation.
PATIENTS AND METHODS
The All women were prescribed the PMTCT antiretroviral regimen described above and none of them received HAART during the study period. The median duration of ZDV prophylaxis between enrolment and delivery was 30 days (IQR: 20-41 days), 94% of these women received the additional labour dose of ZDV and the single-dose of NVP at the beginning of labour.
Distributions of total lymphocytes count and the absolute CD4 count and percentage changed between baseline, month-1 (Table) . The median progression of the CD4 count after delivery was 119 cells/mm3 (IQR: 31-217) without any significant difference according to the class of CD4 count (p=0.156).
The kinetic of the absolute CD4 count in 229 HIV infected women (57%) who had four CD4 measurements available showed a significant increase in the median CD4 absolute count between baseline and month-1 post-partum (p<0.001) as well as a significant but slighter decrease between months 6 and 12 (p=0.004) but no significant difference between months 1 and 6 (p=0.354). In contrast, there was no significant variation in CD4 percentage between the pre-partum and 4 weeks post-partum measurements (p=0.823) and the median variation of the percentage of the CD4 was -0.4 (IQR: -1.9-2.9).
When considering the proportions of women having a CD4 count below the thresholds used for HAART initiation, 17.8% and 30.5% of women had baseline CD4 counts <200 cells/mm 3 were still meeting these criteria one month after delivery.
DISCUSSION
The change of the T-Lymphocytes count and its subsets during pregnancy is well know and already reported by Miotti in Malawi and Ekpini in Côte d'Ivoire (9, 10) and also in developed countries in the European Collaborative Study and the Swiss HIV Pregnancy Cohort (8) and in the US (13, 14) .
All these studies reported an increase of the absolute count between late pregnancy and early postpartum period in HIV-infected mother. This reported is consistent with data observed in our cohort with the absolute CD4 count increased significantly after delivery in women who had been under The variation of the T-lymphocytes and absolute CD4 counts before and after pregnancy related to the hemodilution is due to the progressive rise of cortisol during pregnancy and to the plasma reported that HAART may be associated with adverse pregnancy outcomes such as preterm delivery they initiated at the early period of the pregnancy (5, 6). Moreover, the incidence of rash and hepatic toxicity with NVP-containing HAART, the most commonly used first-line regimen in resource-limited settings, is significantly higher in female patients with higher CD4 cell counts including during pregnancy (7, 17) .The second potential consequence is related to the early immunological response in HIV-infected pregnant women on HAART. Based on the above data, it appears difficult to truly appreciate the effect of HAART in the first six months of treatment initiated during pregnancy as the majority of women show an important increase in CD4+ count after delivery, even without any treatment (9) . It is also likely that a decrease of the absolute CD4 count can be anticipated when women already on HAART become pregnant. Facing this situation, we suggest that the guidelines for initiation HAART among pregnant women in post-partum should be revisited. The similar recommendation was proposed by Mulcahy et al from Ireland who demonstrated that CD4 count in pregnant women do not accurately reflect the need for long-term HAART (18) .
One of the limits of this study is the absence of a control group of HIV negative pregnant women to demonstrate CD4 count variation during pregnancy. Nevertheless, others studies reported an increase of the CD4 count in HIV negative pregnant women in postpartum (10, 13).
In conclusion, it may be important to define specific conditions for HAART initiation in pregnant women in resource-limited settings to go beyond the 2006 WHO recommendations (3). Because of the stability of the CD4 percentage before and after pregnancy, we suggest using exclusively the CD4 percentage instead of CD4 absolute counts for initiating HAART in pregnant women, despite the technical limitations for its routine measurement. In addition further studies are needed to evaluate the use of CD4 percentage in assessing the immunological response to HAART initiated and continued during pregnancy in low-income countries. 
